Evidence map›Paper›PMID 24946229›Full record

ArticleBioconjugate chemistry2014

Engineering protein farnesyltransferase for enzymatic protein labeling applications.

Jonathan K Dozier, Santoshkumar L Khatwani, James W Wollack, Yen-Chih Wang, Claudia Schmidt-Dannert, Mark D Distefano

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Optimization of Metabolic Labeling with Alkyne-Containing Isoprenoid Probes.Methods in molecular biology (Clifton, N.J.) · 2019
    Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Site-Specific PEGylation of Therapeutic Proteins.International journal of molecular sciences · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonathan K DozierDepartment of Chemistry, University of Minnesota , Minneapolis, Minnesota 55455, United States.
Santoshkumar L Khatwani
James W Wollack
Yen-Chih Wang
Claudia Schmidt-Dannert
Mark D Distefano

Funding

Chemistry-Biology Interface Training GrantT32GM008700 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI DISTEFANO, MARK D · 1999 to 2018
$4.0M
Enzymatic Protein LabelingR01GM084152 · NIGMS · UNIVERSITY OF MINNESOTA · PI DISTEFANO, MARK D · 2010 to 2019
$2.6M
NIGMS NIH HHS GM058442NIGMS NIH HHS GM084152NIGMS NIH HHS R01 GM084152NIGMS NIH HHS T32 GM008700
6 · The paper itself

Abstract

Creating covalent protein conjugates is an active area of research due to the wide range of uses for protein conjugates spanning everything from biological studies to protein therapeutics. Protein Farnesyltransferase (PFTase) has been used for the creation of site-specific protein conjugates, and a number of PFTase substrates have been developed to facilitate that work. PFTase is an effective catalyst for protein modification because it transfers Farnesyl diphosphate (FPP) analogues to protein substrates on a cysteine four residues from the C-terminus. While much work has been done to synthesize various FPP analogues, there are few reports investigating how mutations in PFTase alter the kinetics with these unnatural analogues. Herein we examined how different mutations within the PFTase active site alter the kinetics of the PFTase reaction with a series of large FPP analogues. We found that mutating either a single tryptophan or tyrosine residue to alanine results in greatly improved catalytic parameters, particularly in kcat. Mutation of tryptophan 102β to alanine caused a 4-fold increase in kcat and a 10-fold decrease in KM for a benzaldehyde-containing FPP analogue resulting in an overall 40-fold increase in catalytic efficiency. Similarly, mutation of tyrosine 205β to alanine caused a 25-fold increase in kcat and a 10-fold decrease in KM for a coumarin-containing analogue leading to a 300-fold increase in catalytic efficiency. Smaller but significant changes in catalytic parameters were also obtained for cyclo-octene- and NBD-containing FPP analogues. The latter compound was used to create a fluorescently labeled form of Ciliary Neurotrophic Factor (CNTF), a protein of therapeutic importance. Additionally, computational modeling was performed to study how the large non-natural isoprenoid analogues can fit into the active sites enlarged via mutagenesis. Overall, these results demonstrate that PFTase can be improved via mutagenesis in ways that will be useful for protein engineering and the creation of site-specific protein conjugates.

Indexed as

Photoaffinity LabelsProtein PrenylationAlkyl and Aryl TransferasesBinding SitesCatalysisCatalytic DomainHumansKineticsModels, MolecularMolecular StructureMutationPolyisoprenyl PhosphatesProtein EngineeringSesquiterpenesSubstrate SpecificityAlkyl and Aryl Transferasesfarnesyl pyrophosphatep21(ras) farnesyl-protein transferasePhotoaffinity LabelsPolyisoprenyl PhosphatesSesquiterpenes

Identifiers

PMID24946229
PMCPMC4103756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.